1689509-92-9Relevant academic research and scientific papers
Novel compound and glucose detection method using same
-
Paragraph 0044-0048, (2021/09/07)
The present invention relates to a novel compound having excellent glucose detection effect and a method for detecting glucose using the same. The novel compound of the present invention advantageously enhances the fluorescence characteristics of the improved Red shift and Stokes shift spectral properties, as well as providing excellent glucose sensitivity, and has an obvious commercial advantage of a simpler and less expensive optical sensing system upon insertion or proximity use in the human body.
MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
-
Page/Page column 110; 119, (2020/10/18)
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
2-METHYL-QUINAZOLINES
-
Page/Page column 319-320, (2018/10/19)
The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
ANTICANCER COMPOUNDS
-
Paragraph 0177, (2018/05/03)
The invention provides compounds having the general formula I: and salts thereof, wherein the variables RA, RB, RC, L1, L2, L3, A, B, C, X, Y, Z, E, m, n, and p have the meaning as describe
N-(1-Benzyl-3,5-dimethyl?1H?pyrazol-4-yl)benzamides: Antiproliferative activity and effects on mTORC1 and autophagy
Ai, Teng,Willett, Rose,Williams, Jessica,Ding, Rui,Wilson, Daniel J.,Xie, Jiashu,Kim, Do-Hyung,Puertollano, Rosa,Chen, Liqiang
supporting information, p. 90 - 95 (2017/12/13)
Guided by antiproliferative activity in MIA PaCa-2 cells, we have performed preliminary structure?activity relationship studies on N-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)benzamides. Two selected compounds showed submicromolar antiproliferative activity
